David A. Siegel Kal Vista Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 22,822 shares of KALV stock, worth $222,742. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,822
Previous 38,322
40.45%
Holding current value
$222,742
Previous $443,000
56.43%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding KALV
# of Institutions
135Shares Held
52MCall Options Held
551KPut Options Held
98K-
Vr Adviser, LLC New York, NY6.25MShares$61 Million8.73% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.91MShares$48 Million1.73% of portfolio
-
Tang Capital Management LLC San Diego, CA4.89MShares$47.8 Million3.11% of portfolio
-
Vestal Point Capital, LP New York, NY4.77MShares$46.6 Million2.4% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$36 Million2.3% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $240M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...